Valuation: Genexine, Inc.

Market Cap 243B 183M 163M 151M 137M 257M 17.33B 261M 1.81B 711M 9.07B 686M 672M 28.92B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 185M 165M 153M 138M 260M 17.54B 264M 1.83B 720M 9.18B 694M 680M 29.27B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
21/09 Genexine, Inc.(KOSDAQ:A095700) dropped from S&P Global BMI Index CI
15/09 Genexine Presents Preclinical Data For GX-BP1 SOX2 BioPROTAC At 2026 World Conference On Lung Cancer CI
29/04 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
17/03 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
16/03 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
01/10/25 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
23/09/25 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/03/25 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
01/10/24 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/07/24 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
26/06/24 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/05/24 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/11/23 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day-0.95%
1 week-5.11%
Current month-4.41%
1 month-10.34%
3 months+13.54%
6 months-60.12%
Current year-44.50%
1 week 2,510
Extreme 2510
2,695
1 month 2,510
Extreme 2510
3,625
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
11,870
5 years 2,140
Extreme 2140
55,461.54
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 26/03/2025
Chief Executive Officer 61 27/01/2023
Corporate Officer/Principal 49 01/01/2022
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 29/03/2022
Director/Board Member 61 27/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
22/10/24 Others 156,632 0.3773%
22/10/24 Others

Chief Executive Officer

1,691,165 4.0741%
22/10/24 Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%-5.11%-50.66%-65.29% 89.05M
+0.79%-6.16%+49.32%+74.50% 66.34B
+1.92%+10.35%+13.02%+87.74% 52.92B
+6.91%+8.57%+6.88%+72.12% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.18%-0.56%+37.31%+7.17% 26.17B
+2.36%+5.34%+30.98%+26.07% 23.37B
Average +2.20%+1.16%+41.48%+104.22% 38.76B
Weighted average by Cap. +2.78%+1.99%+51.07%+127.79%

Financials

2022 2023
Net sales 16.14B 12.15M 10.82M 10.03M 9.09M 17.07M 1.15B 17.36M 120M 47.26M 603M 45.59M 44.64M 1.92B 4.43B 3.33M 2.97M 2.75M 2.49M 4.68M 316M 4.76M 33M 12.96M 165M 12.5M 12.24M 527M
Net income -55.97B -42.15M -37.52M -34.77M -31.51M -59.22M -3.99B -60.21M -417M -164M -2.09B -158M -155M -6.67B -66.87B -50.36M -44.83M -41.54M -37.65M -70.75M -4.77B -71.93M -498M -196M -2.5B -189M -185M -7.96B
Net Debt 62.14B 46.8M 41.65M 38.6M 34.98M 65.74M 4.43B 66.84M 463M 182M 2.32B 176M 172M 7.4B 2.94B 2.22M 1.97M 1.83M 1.66M 3.12M 210M 3.17M 21.95M 8.62M 110M 8.32M 8.15M 351M
Projected Income Statement - Annual - Genexine, Inc.
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
20/10/26 KRW 2,600.00 -0.95% 72,640
19/10/26 KRW 2,625.00 -0.76% 76,448
16/10/26 KRW 2,645.00 +2.52% 87,166
15/10/26 KRW 2,580.00 -4.09% 186,558
14/10/26 KRW 2,690.00 -1.82% 118,273
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Genexine, Inc.
  1. Stock Market
  2. Stocks
  3. A095700 Stock